Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors

Which way shall we go?

D. A. Sabbah, M. G. Brattain, Haizhen Andrew Zhong

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signaling pathway is a central regulator in cell proliferation, growth, and angiogenesis. Inhibition of this pathway therefore is a major strategy for cancer chemotherapy. In order to induce the maximal therapeutic outcome in cancer treatment, vertical inhibition of the PI3K/AKT/mTOR pathway or horizontal inhibition of PI3K/AKT/mTOR and other kinases has been reported. In this review, we discuss the drug design and clinical development of dual inhibitors of PI3K and mTOR as well as the mTOR-selective inhibitors, classified based on the mechanism of action and the chemical structures. Structural determinants for increasing selectivity toward PI3Kα or mTOR are revealed from the structure-activity relationship of the reported inhibitors. Current clinical development in combination therapy of inhibitors involving in the PI3K/AKT/mTOR pathway is also discussed.

Original languageEnglish (US)
Pages (from-to)5528-5544
Number of pages17
JournalCurrent Medicinal Chemistry
Volume18
Issue number36
StatePublished - Dec 1 2011

Fingerprint

Phosphatidylinositol 3-Kinase
Pharmacologic Actions
Oncology
Chemotherapy
Drug Design
Cell proliferation
Structure-Activity Relationship
Neoplasms
Phosphotransferases
Therapeutics
Cell Proliferation
Drug Therapy
Growth
Pharmaceutical Preparations

Keywords

  • And cancer
  • Kinase inhibitors
  • PI3Kα
  • Rapamycin
  • Selectivity
  • mTORC1
  • mTORC2

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors : Which way shall we go? / Sabbah, D. A.; Brattain, M. G.; Zhong, Haizhen Andrew.

In: Current Medicinal Chemistry, Vol. 18, No. 36, 01.12.2011, p. 5528-5544.

Research output: Contribution to journalArticle

@article{30dc19df530e4eec93db2ac9a8733195,
title = "Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: Which way shall we go?",
abstract = "The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signaling pathway is a central regulator in cell proliferation, growth, and angiogenesis. Inhibition of this pathway therefore is a major strategy for cancer chemotherapy. In order to induce the maximal therapeutic outcome in cancer treatment, vertical inhibition of the PI3K/AKT/mTOR pathway or horizontal inhibition of PI3K/AKT/mTOR and other kinases has been reported. In this review, we discuss the drug design and clinical development of dual inhibitors of PI3K and mTOR as well as the mTOR-selective inhibitors, classified based on the mechanism of action and the chemical structures. Structural determinants for increasing selectivity toward PI3Kα or mTOR are revealed from the structure-activity relationship of the reported inhibitors. Current clinical development in combination therapy of inhibitors involving in the PI3K/AKT/mTOR pathway is also discussed.",
keywords = "And cancer, Kinase inhibitors, PI3Kα, Rapamycin, Selectivity, mTORC1, mTORC2",
author = "Sabbah, {D. A.} and Brattain, {M. G.} and Zhong, {Haizhen Andrew}",
year = "2011",
month = "12",
day = "1",
language = "English (US)",
volume = "18",
pages = "5528--5544",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "36",

}

TY - JOUR

T1 - Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors

T2 - Which way shall we go?

AU - Sabbah, D. A.

AU - Brattain, M. G.

AU - Zhong, Haizhen Andrew

PY - 2011/12/1

Y1 - 2011/12/1

N2 - The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signaling pathway is a central regulator in cell proliferation, growth, and angiogenesis. Inhibition of this pathway therefore is a major strategy for cancer chemotherapy. In order to induce the maximal therapeutic outcome in cancer treatment, vertical inhibition of the PI3K/AKT/mTOR pathway or horizontal inhibition of PI3K/AKT/mTOR and other kinases has been reported. In this review, we discuss the drug design and clinical development of dual inhibitors of PI3K and mTOR as well as the mTOR-selective inhibitors, classified based on the mechanism of action and the chemical structures. Structural determinants for increasing selectivity toward PI3Kα or mTOR are revealed from the structure-activity relationship of the reported inhibitors. Current clinical development in combination therapy of inhibitors involving in the PI3K/AKT/mTOR pathway is also discussed.

AB - The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signaling pathway is a central regulator in cell proliferation, growth, and angiogenesis. Inhibition of this pathway therefore is a major strategy for cancer chemotherapy. In order to induce the maximal therapeutic outcome in cancer treatment, vertical inhibition of the PI3K/AKT/mTOR pathway or horizontal inhibition of PI3K/AKT/mTOR and other kinases has been reported. In this review, we discuss the drug design and clinical development of dual inhibitors of PI3K and mTOR as well as the mTOR-selective inhibitors, classified based on the mechanism of action and the chemical structures. Structural determinants for increasing selectivity toward PI3Kα or mTOR are revealed from the structure-activity relationship of the reported inhibitors. Current clinical development in combination therapy of inhibitors involving in the PI3K/AKT/mTOR pathway is also discussed.

KW - And cancer

KW - Kinase inhibitors

KW - PI3Kα

KW - Rapamycin

KW - Selectivity

KW - mTORC1

KW - mTORC2

UR - http://www.scopus.com/inward/record.url?scp=84055192519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055192519&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 5528

EP - 5544

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 36

ER -